Crawford B - Search Results

1

Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis.

Strand V, Cohen S, Crawford B, Smolen JS, Scott DL; Leflunomide Investigators Groups. Strand V, et al. Among authors: crawford b. Rheumatology (Oxford). 2004 May;43(5):640-7. doi: 10.1093/rheumatology/keh140. Epub 2004 Mar 23. Rheumatology (Oxford). 2004. PMID: 15039493 Clinical Trial.

2

Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies.

Strand V, Crawford B. Strand V, et al. Among authors: crawford b. Expert Rev Pharmacoecon Outcomes Res. 2005 Jun;5(3):317-26. doi: 10.1586/14737167.5.3.317. Expert Rev Pharmacoecon Outcomes Res. 2005. PMID: 19807601

3

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.

Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B; Leflunomide Rheumatoid Arthritis Investigators Groups. Strand V, et al. Among authors: crawford b. J Rheumatol. 2005 Apr;32(4):590-601. J Rheumatol. 2005. PMID: 15801012

4

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.

Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM. Kremer JM, et al. Among authors: crawford b. Ann Intern Med. 2002 Nov 5;137(9):726-33. doi: 10.7326/0003-4819-137-9-200211050-00007. Ann Intern Med. 2002. PMID: 12416946 Clinical Trial.

5

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.

Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V. Kremer J, et al. Among authors: crawford b. J Rheumatol. 2004 Aug;31(8):1521-31. J Rheumatol. 2004. PMID: 15290730 Clinical Trial.

6

Longterm treatment benefits are best reflected by patient reported outcomes.

Strand CV, Crawford B. Strand CV, et al. Among authors: crawford b. J Rheumatol. 2007 Dec;34(12):2317-9. J Rheumatol. 2007. PMID: 18061963 No abstract available.

7

The Use of patient Reported Outcome Measures for Rheumatoid Arthritis in Japan: A Systematic Literature Review.

Tang AC, Kim H, Crawford B, Ishii T, Treuer T. Tang AC, et al. Among authors: crawford b. Open Rheumatol J. 2017 Apr 28;11:43-52. doi: 10.2174/1874312901711010043. eCollection 2017. Open Rheumatol J. 2017. PMID: 28553419 Free PMC article. Review.

8

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo.

Strand V, Aranow C, Cardiel MH, Alarcón-Segovia D, Furie R, Sherrer Y, Tumlin J, Wallace DJ, Crawford B; LJP 394 Investigator Consortium. Strand V, et al. Among authors: crawford b. Lupus. 2003;12(9):677-86. doi: 10.1191/0961203303lu440oa. Lupus. 2003. PMID: 14514130 Clinical Trial.

9

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases.

Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D. Strand V, et al. Among authors: crawford b. Ann Rheum Dis. 2009 Dec;68(12):1800-4. doi: 10.1136/ard.2009.115550. Ann Rheum Dis. 2009. PMID: 19910301 Free PMC article.

10

An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.

Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, Cohen S, Felson D. Pincus T, et al. Among authors: crawford b. Arthritis Rheum. 2003 Mar;48(3):625-30. doi: 10.1002/art.10824. Arthritis Rheum. 2003. PMID: 12632413 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results